[
    {
        "source_PMID": "9742977",
        "BACKGROUND: In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks.": [
            " question: Does intensive blood-glucose control with insulin or sulphonylurea decrease the progression of microvascular disease?"
        ],
        "This study investigated whether intensive glucose control with metformin has any specific advantage or disadvantage.": [
            " question: Is metformin a specific advantage or disadvantage?"
        ],
        "METHODS: Of 4075 patients recruited to UKPDS in 15 centres, 1704 overweight (>120% ideal bodyweight) patients with newly diagnosed type 2 diabetes, mean age 53 years, had raised fasting plasma glucose (FPG; 6.1-15.0 mmol/L) without hyperglycaemic symptoms after 3 months' initial diet.": [
            " question: What questions did the UKPDS generate?"
        ],
        "753 were included in a randomised controlled trial, median duration 10.7 years, of conventional policy, primarily with diet alone (n=411) versus intensive blood-glucose control policy with metformin, aiming for FPG below 6 mmol/L (n=342).": [
            " question: How many people were included in a randomised controlled trial?"
        ],
        "A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose control with chlorpropamide (n=265), glibenclamide (n=277), or insulin (n=409).": [
            " question: How did the secondary analysis compare the patients allocated metformin with the overweight patients?"
        ],
        "The primary outcome measures were aggregates of any diabetes-related clinical endpoint, diabetes-related death, and all-cause mortality.": [
            " question: What were the primary outcome measures?"
        ],
        "In a supplementary randomised controlled trial, 537 non-overweight and overweight patients, mean age 59 years, who were already on maximum sulphonylurea therapy but had raised FPG (6.1-15.0 mmol/L) were allocated continuing sulphonylurea therapy alone (n=269) or addition of metformin (n=268).": [
            " question: What did the supplementary randomised controlled trial generate?"
        ],
        "FINDINGS: Median glycated haemoglobin (HbA1c) was 7.4% in the metformin group compared with 8.0% in the conventional group.": [
            " question: What was the mean glycated haemoglobin in the metformin group?"
        ],
        "Patients allocated metformin, compared with the conventional group, had risk reductions of 32% (95% CI 13-47, p=0.002) for any diabetes-related endpoint, 42% for diabetes-related death (9-63, p=0.017), and 36% for all-cause mortality (9-55, p=0.011).": [
            " question: Did metformin reduce the risk of diabetes-related death by 42%?"
        ],
        "Among patients allocated intensive blood-glucose control, metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint (p=0.0034), all-cause mortality (p=0.021), and stroke (p=0.032).": [
            " question: Metformin showed a greater effect than chlorpropamide, glibenclamide or insulin for any diabetes-related endpoint?"
        ],
        "Early addition of metformin in sulphonylurea-treated patients was associated with an increased risk of diabetes-related death (96% increased risk [95% CI 2-275], p=0.039) compared with continued sulphonylurea alone.": [
            " question: Was early addition of metformin associated with an increased risk of diabetes-related death?"
        ],
        "A combined analysis of the main and supplementary studies showed fewer metformin-allocated patients having diabetes-related endpoints (risk reduction 19% [2-33], p=0.033).": [
            " question: What did the combined analysis of the main and supplementary studies show?"
        ],
        "Epidemiological assessment of the possible association of death from diabetes-related causes with the concurrent therapy of diabetes in 4416 patients did not show an increased risk in diabetes-related death in patients treated with a combination of sulphonylurea and metformin (risk reduction 5% [-33 to 32], p=0.78).": [
            " question: Did the combination of sulphonylurea and metformin increase the risk of diabetes-related death?"
        ],
        "INTERPRETATION: Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.": [
            " question: Is metformin the first-line pharmacological therapy of choice in overweight diabetic patients?"
        ]
    },
    {
        "source_PMID": "32891604",
        "To evaluate the effect of multifactorial intervention on the onset and progression of diabetic kidney disease in the patients with type 2 diabetes, we analyzed the effects of intensified multifactorial intervention by step-wise intensification of medications and life-style modifications (intensive therapy treatment targets; HbA1c under 6.2%, blood pressure under 120/75 mmHg, low-density lipoprotein cholesterol under 80 mg/dL) comparing with the guideline-based standard care (conventional therapy treatment targets: HbA1c under 6.9%, blood pressure under 130/80 mmHg, low-density lipoprotein cholesterol under 120 mg/dL) on diabetic kidney disease.": [
            " question: What type of questions were generated by the study?",
            " question: What are the guidelines for diabetic kidney disease?"
        ],
        "A total of 2540 eligible patients in the Japan Diabetes Optimal Integrated Treatment for three major risk factors of cardiovascular diseases (J-DOIT3) cohort were randomly assigned to intensive therapy (1269) and conventional therapy (1271) and treated for a median of 8.5 years.": [
            " question: How many patients were randomly assigned to intensive therapy and conventional therapy?"
        ],
        "The prespecified kidney outcome measure was a composite of progression from normoalbuminuria to microalbuminuria or progression from normoalbuminuria to macroalbuminuria or progression from microalbuminuria to macroalbuminuria, serum creatinine levels elevated by two-fold or more compared to baseline, or kidney failure.": [
            " question: What was the prespecified kidney outcome measure?"
        ],
        "Primary analysis was carried out on the intention-to-treat population.": [
            " question: What was the primary analysis carried out on the intention-to-treat population?"
        ],
        "Changes in the estimated glomerular filtration rate and albuminuria were also analyzed.": [
            " question: What changes in albuminuria and glomerular filtration rate were also analyzed?"
        ],
        "A total of 438 kidney events occurred (181 in the intensive therapy group and 257 in the conventional therapy group).": [
            " question: How many kidney events occurred in the intensive therapy group?"
        ],
        "Intensive therapy was associated with a significant 32% reduction in kidney events compared to conventional therapy and was associated with a change in HbA1c at one year from study initiation.": [
            " question: Was intensive therapy associated with a significant reduction in kidney events?"
        ],
        "Thus, prespecified analysis shows that intensified multifactorial intervention significantly reduced the onset and progression of diabetic kidney disease compared to currently recommended care.": [
            " question: Did intensified multifactorial intervention significantly reduce the onset and progression of diabetic kidney disease?"
        ]
    },
    {
        "source_PMID": "32215272",
        "Diabetic peripheral neuropathy is one of the most common chronic complications of diabetics which causes nerve damage and muscle strength decrease in patients.": [
            " question: What is the cause of diabetic peripheral neuropathy?"
        ],
        "This in turn results in imbalance leading to the diabetic patients' daily activity disparity.": [
            " question: What is the result of the imbalance?"
        ],
        "The present investigation was conducted to specifically study the effects of combined training (resistance-aerobic) on serum kinesin-1 and physical function in type 2 diabetes patients with diabetic peripheral neuropathy.": [
            " question: What was the purpose of the study?"
        ],
        "24 diabetic neuropathic females were randomly to be selected out and divided into two experimental and control groups.": [
            " question: How many diabetic neuropathic females were randomly selected?"
        ],
        "The experimental group received resistance-aerobic training for 3 sessions during eight weeks.": [
            " question: What type of training did the experimental group receive?"
        ],
        "The exercise training included resistance exercises with 2-3 sets, 6-7 exercise stations, 8-12 repetitions (reps), and 3-5 minutes of rest in between the exercises, and the aerobic exercises contained 50-65% of heart rate reserve (HRR) for 3 minutes with 30 seconds of rest interval between sets and 5-10 repetitions.": [
            " question: What type of questions were asked during the exercise training?"
        ],
        "Results show that the serum kinesin-1 level and aerobic endurance declined after eight weeks of combined (resistance-aerobic) exercise training, but this decrease was not significant.": [
            " question: Did the serum kinesin-1 level and aerobic endurance decline after eight weeks of combined (resistance-aerobic) training?"
        ],
        "The upper body strength increased but it was not significant, while the lower body showed a significant strength increase.": [
            " question: Did the lower body show a significant increase in strength?"
        ],
        "With regard to the progressive nature of diabetic peripheral neuropathy, it seems that even the little changes resulting from the combined exercise training can be useful.": [
            " question: What can even small changes resulting from combined exercise training be useful?"
        ],
        "Nevertheless, more research is required in this area.": [
            " question: Is there more research to be done in this area?"
        ]
    },
    {
        "source_PMID": "30012135",
        "BACKGROUND: Lithium is the gold-standard treatment for bipolar disorder, is highly effective in treating major depressive disorder, and has anti-suicidal properties.": [
            " question: Does lithium have anti-suicidal properties?"
        ],
        "However, clinicians are increasingly avoiding lithium largely due to fears of renal toxicity.": [
            " question: Why are clinicians avoiding lithium?"
        ],
        "Nephrogenic Diabetes Insipidus (NDI) occurs in 15-20% of lithium users and predicts a 2-3 times increased risk of chronic kidney disease (CKD).": [
            " question: What does NDIA do?"
        ],
        "We recently found that use of statins is associated with lower NDI risk in a cross-sectional study.": [
            " question: Are statins associated with lower NDI risk?"
        ],
        "In this current paper, we describe the methodology of a randomized controlled trial (RCT) to treat lithium-induced NDI using atorvastatin.": [
            " question: What are the results of the RCT?"
        ],
        "METHODS: We will conduct a 12-week, double-blind placebo-controlled RCT of atorvastatin for lithium-induced NDI at McGill University, Montreal, Canada.": [
            " question: What are the results of the RCT?"
        ],
        "We will recruit 60 current lithium users, aged 18-85, who have indicators of NDI, which we defined as urine osmolality (UOsm) <\u2009600\u00a0mOsm/kg after 10-h fluid restriction.": [
            " question: How many current lithium users will be recruited?"
        ],
        "We will randomize patients to atorvastatin (20\u00a0mg/day) or placebo for 12\u00a0weeks.": [
            " question: How many weeks will patients receive atorvastatin or placebo?"
        ],
        "We will examine whether this improves measures of NDI: UOsm and aquaporin (AQP2) excretion at 12-week follow-up, adjusted for baseline.": [
            " question: Will this improve measures of NDI?"
        ],
        "RESULTS: Not applicable.": [
            " question: What is the answer to the question?"
        ],
        "CONCLUSION: The aim of this clinical trial is to provide preliminary data about the efficacy of atorvastatin in treating NDI.": [
            " question: What is the purpose of this clinical trial?"
        ],
        "If successful, lithium could theoretically be used more safely in patients with a reduced subsequent risk of CKD, hypernatremia, and acute kidney injury (AKI).": [
            " question: Could lithium be used more safely in patients with CKD, hypernatremia, and AKI?"
        ],
        "If future definitive trials confirm this, this could potentially allow more patients to benefit from lithium, while minimizing renal risk.": [
            " question: Is there a possibility of more patients benefiting from lithium?"
        ],
        "TRIAL REGISTRATION: ClinicalTrials.gov NCT02967653 .": [
            " question: ClinicalTrials.gov NCT02967653"
        ],
        "Registered in February 2017.": [
            " question: What was the last time a user was registered?"
        ]
    },
    {
        "source_PMID": "31295292",
        "BACKGROUND: Therapeutic footwear becomes the first treatment line in the prevention of diabetic foot ulcer and future complications of diabetes.": [
            " question: Therapeutic footwear is the first treatment line in the prevention of diabetic foot ulcers and future complications of diabetes?"
        ],
        "Previous studies and the International Working Group on the Diabetic Foot have described therapeutic footwear as a protective factor to reduce the risk of re-ulceration.": [
            " question: What has the International Working Group on the Diabetic Foot described therapeutic footwear as?"
        ],
        "In this study, we aimed to analyze the efficacy of a rigid rocker sole to reduce the recurrence rate of plantar ulcers in patients with diabetic foot.": [
            " question: What was the purpose of this study?"
        ],
        "METHODS: Between June 2016 and December 2017, we conducted a randomized controlled trial in a specialized diabetic foot unit.": [
            " question: What questions did the randomized controlled trial ask?"
        ],
        "PARTICIPANTS AND INTERVENTION: Fifty-one patients with diabetic neuropathy who had a recently healed plantar ulcer were randomized consecutively into the following two groups: therapeutic footwear with semi-rigid sole (control) or therapeutic footwear with a rigid rocker sole (experimental).": [
            " question: Who were the participants in the study?"
        ],
        "All patients included in the study were followed up for 6 months (one visit each 30 \u00b1 2 days) or until the development of a recurrence event.": [
            " question: How long were patients followed up?"
        ],
        "MAIN OUTCOME AND MEASURE: Primary outcome measure was recurrence of ulcers in the plantar aspect of the foot.": [
            " question: What was the primary outcome measure of ulcers in the plantar aspect of the foot?"
        ],
        "FINDINGS: A total of 51 patients were randomized to the control and experimental groups.": [
            " question: What were the results of the study?"
        ],
        "The median follow-up time was 26 [IQR-4.4-26.1] weeks for both groups.": [
            " question: How long was the median follow-up time for both groups?"
        ],
        "On an intention-to-treat basis, 16 (64%) and 6 (23%) patients in the control and experimental groups had ulcer recurrence, respectively.": [
            " question: Did ulcer recurrence occur in the control and experimental groups?"
        ],
        "Among the group with >60% adherence to therapeutic footwear, multivariate analysis showed that the rigid rocker sole improved ulcer recurrence-free survival time in diabetes patients with polyneuropathy and DFU history (P = 0.019; 95% confidence interval, 0.086-0.807; hazard ratio, 0.263).": [
            " question: What did the multivariate analysis show about the rocker sole?"
        ],
        "CONCLUSIONS: We recommend the use of therapeutic footwear with a rigid rocker sole in patients with diabetes with polyneuropathy and history of diabetic foot ulcer to reduce the risk of plantar ulcer recurrence.": [
            " question: What kind of questions do diabetic foot ulcers raise?"
        ],
        "TRIAL REGISTRATION: ClinicalTrials.gov NCT02995863.": [
            " question: ClinicalTrials.gov NCT02995863."
        ]
    },
    {
        "source_PMID": "32621644",
        "OBJECTIVE: Lithium remains an important treatment for mood disorders but is associated with kidney disease.": [
            " question: What is the OBJECTIVE of lithium?"
        ],
        "Nephrogenic diabetes insipidus (NDI) is associated with up to 3-fold risk of incident chronic kidney disease among lithium users.": [
            " question: What is the risk of chronic kidney disease among lithium users?"
        ],
        "There are limited randomized controlled trials (RCT) for treatments of lithium-induced NDI, and existing therapies can be poorly tolerated.": [
            " question: Are there any randomized controlled trials for lithium-induced NDI?"
        ],
        "Therefore, novel treatments are needed for lithium-induced NDI.": [
            " question: What are new treatments needed for lithium-induced NDI?"
        ],
        "METHOD: We conducted a 12-week double-blind pilot RCT to assess the feasibility and efficacy of 20\u00a0mg/d atorvastatin vs placebo in the treatment of NDI in chronic lithium users.": [
            " question: What was the purpose of the pilot RCT?"
        ],
        "Patients, recruited between September 2017 and October 2018, were aged 18 to 85, currently on a stable dose of lithium, and determined to have NDI.": [
            " question: What were the patients determined to have NDI?"
        ],
        "RESULTS: Urinary osmolality (UOsm) at 12\u00a0weeks adjusted for baseline was not statistically different between groups (+39.6\u00a0mOsm/kg [95% CI, -35.3, 114.5] in atorvastatin compared to placebo groups).": [
            " question: Was UOsm statistically different between groups?"
        ],
        "Secondary outcomes of fluid intake and aquaporin-2 excretions at 12\u00a0weeks adjusted for baseline were -0.13 L [95% CI, -0.54, 0.28] and 98.68 [95% CI, -190.34, 387.70], respectively.": [
            " question: What were the secondary outcomes of aquaporin-2 excretion?"
        ],
        "A moderate effect size was observed for improvements in baseline UOsm by \u2265100\u00a0mOsm/kg at 12\u00a0weeks in patients who received atorvastatin compared to placebo (38.45% (10/26) vs 22.58% (7/31); Cohen's d\u00a0=\u00a00.66).": [
            " question: Did atorvastatin have a significant effect on baseline UOsm?"
        ],
        "CONCLUSION: Among lithium users with NDI, atorvastatin 20\u00a0mg/d did not significantly improve urinary osmolality compared to placebo over a 12-week period.": [
            " question: Did atorvastatin significantly improve urinary osmolality?"
        ],
        "Larger confirmatory trials with longer follow-up periods may help to further assess the effects of statins on NDI, especially within patients with more severe NDI.": [
            " question: Do larger confirmatory trials with longer follow-up periods help to further assess the effects of statins on NDI?"
        ]
    },
    {
        "source_PMID": "32321301",
        "OBJECTIVE: The aim of this study is to investigate the effects of the HbA1c level and the duration of diabetes mellitus on the corneal endothelium morphology and to compare between healthy individuals and diabetes mellitus patients with non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.": [
            " question: What is the purpose of this study?"
        ],
        "MATERIAL AND METHODS: Ninety patients who applied to the Health Sciences University Ulucanlar Eye Training and Research Hospital between January 2016 and January 2017 were included in this prospective randomized study.": [
            " question: What was the purpose of the study?"
        ],
        "In the study, 45 diabetes mellitus patients and 45 healthy individuals were evaluated.": [
            " question: How many healthy individuals were included in the study?"
        ],
        "The diabetes patients were compared in terms of HbA1c level, diabetes mellitus duration, corneal endothelial cell density, coefficient of variation, standard deviation, and hexagonality with healthy control group.": [
            " question: How were the diabetes patients compared to the healthy control group?"
        ],
        "RESULTS: A statistically significant difference was found in the endothelial cell densitometer, coefficient of variation, and standard deviation measurements between the diabetes mellitus patients and the control (healthy) group.": [
            " question: What were the results of the endothelial cell densitometer?"
        ],
        "But, there was no statistically significant difference between 6A (hexagonality) and central corneal thickness measurements.": [
            " question: Was there a statistically significant difference between 6A (hexagonality) and central corneal thickness measurements?"
        ],
        "There was a negative correlation between HbA1c levels and diabetes mellitus times and endothelial cell densitometer values in the patients with diabetes mellitus diagnosis and standard deviation values in the positive direction.": [
            " question: Is there a positive or negative correlation between HbA1c levels and diabetes mellitus times?"
        ],
        "There was a statistically significant difference between diabetes mellitus patients with the diagnosis of non-proliferative diabetic retinopathy and proliferative diabetic retinopathy in the endothelial cell densitometer and standard deviation values.": [
            " question: Was there a statistically significant difference between non-proliferative diabetic retinopathy patients and diabetic mellitus patients?"
        ],
        "But there was not any statistically significant difference between coefficient of variation, 6A, and central corneal thickness values.": [
            " question: Was there any statistically significant difference between the coefficient of variation, 6A, and central corneal thickness values?"
        ],
        "CONCLUSION: The endothelial cell densitometer in diabetes mellitus patients with retinopathy is lower than that in healthy individuals.": [
            " question: Is the endothelial cell densitometer lower in diabetes mellitus patients with retinopathy than in healthy individuals?"
        ],
        "There is a negative correlation between retinopathy severity and corneal endothelial cell density.": [
            " question: Is there a negative correlation between corneal endothelial cell density and corneal retinopathy severity?"
        ],
        "Diabetes affects negatively not only vascular tissues but also avascular cornea.": [
            " question: How does diabetes affect the cornea?"
        ]
    },
    {
        "source_PMID": "34889293",
        "BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes mellitus.": [
            " question: What does DPN do?"
        ],
        "The main clinical manifestations of DPN include pain, numbness, paraesthesia, and weakness of the lower limbs which often leads to diabetic foot ulceration, eventually resulting in amputation.": [
            " question: What are the main clinical manifestations of DPN?"
        ],
        "Based on Traditional Chinese Medicine theory, moxibustion has a great effect on treating and preventing DPN.": [
            " question: Does moxibustion have a positive effect on DPN?"
        ],
        "However, randomized clinical trials done to evaluate the efficacy of this treatment are still lacking.": [
            " question: Are there any randomized clinical trials done to evaluate the efficacy of this treatment?"
        ],
        "Hence, this study is carried out to evaluate the effectiveness and safety of moxibustion therapy on diabetic peripheral neuropathy.": [
            " question: What is the purpose of this study?"
        ],
        "METHODS: This study will be a pilot, interventional, randomized, 2-armed, parallel, singled-masked, controlled trial.": [
            " question: What type of questions will be asked in this study?"
        ],
        "A total of 40 diabetes mellitus patients with peripheral neuropathy will be recruited and assigned randomly into 2 groups (moxibustion group and waiting group) at a 1:1 ratio.": [
            " question: How many patients will be randomly assigned?"
        ],
        "This trial consists of an 8-week intervention period and a 4-week follow-up period.": [
            " question: How long is the follow-up period?"
        ],
        "During the intervention period, the moxibustion group will take 3 moxibustion sessions per week, whereas no intervention will be done on the waiting group to act as the control group.": [
            " question: What will the moxibustion group do during the intervention period?"
        ],
        "The outcome will be assessed by an outcome assessor who is unaware of the group assignment.": [
            " question: Who will assess the outcome?"
        ],
        "The primary outcome will be pain assessment measured with algometry, Leeds Assessment of Neuropathic Symptoms and Signs pain scale, visual analogue scale, and neuropathy pain scale.": [
            " question: What is the primary outcome of the Leeds Assessment of Neuopathic Symptoms and Signs?"
        ],
        "The secondary outcome will be an evaluation of functional performance capacity with 6 minutes walking test, evaluation of the Foot and Ankle Ability Measure, and serum HbA1c and albumin levels.": [
            " question: What is the secondary outcome of the Foot and Ankle Ability Measure?"
        ],
        "DISCUSSION: We hope that this trial will provide valuable insights on the efficacy of moxibustion in the management of diabetic peripheral neuropathy.": [
            " question: What kind of questions will this trial generate?"
        ],
        "TRIAL REGISTRATION: ClinicalTrials.gov Registry No.": [
            " question: What is ClinicalTrials.gov's registry number?"
        ],
        ": NCT04894461 (URL: https://clinicaltrials.gov/ct2/show/NCT04894461?term=NCT04894461&draw=2&rank=1) Registered on May 20, 2021.": [
            " question: What is the name of the NCT?"
        ]
    },
    {
        "source_PMID": "7587918",
        "To examine whether intensive glycemic control could decrease the frequency or severity of diabetic microvascular complications, we performed a prospective study of Japanese patients with non-insulin-dependent diabetes mellitus (NIDDM) treated with multiple insulin injection treatment.": [
            " question: Did intensive glycemic control decrease the frequency or severity of diabetic microvascular complications?"
        ],
        "A total of 110 patients with NIDDM was randomly assigned to multiple insulin injection treatment group (MIT group) or to conventional insulin injection treatment group (CIT group).": [
            " question: Who was randomly assigned to MIT or CIT groups?"
        ],
        "Fifty-five NIDDM patients who showed no retinopathy and urinary albumin excretions < 30 mg/24 h at the baseline were evaluated in the primary-prevention cohort, and the other 55 NIDDM patients who showed simple retinopathy and urinary albumin excretions < 300 mg/24 h were evaluated in the secondary-intervention cohort.": [
            " question: How were the NIDDM patients evaluated in the secondary-intervention cohort?"
        ],
        "The appearance and the progression of retinopathy, nephropathy and neuropathy were evaluated every 6 months over a 6-year period.": [
            " question: How often were retinopathy, nephropathy, and neuropathy evaluated?"
        ],
        "The worsening of complications in this study was defined as an increase of 2 or more steps in the 19 stages of the modified ETDRS interim scale for retinopathy and an increase of one or more steps in 3 stages (normoalbuminuria, microalbuminuria and albuminuria) for nephropathy.": [
            " question: What was the worsening of complications?"
        ],
        "The cumulative percentages of the development and the progression in retinopathy after 6 years were 7.7% for the MIT group and 32.0% for the CIT group in the primary-prevention cohort (P = 0.039), and 19.2% for MIT group and 44.0% for CIT group in the secondary-intervention cohort (P = 0.049).": [
            " question: What were the cumulative percentages of the development and the progression in retinopathy after 6 years?"
        ],
        "The cumulative percentages of the development and the progression in nephropathy after 6 years were 7.7% for the MIT group and 28.0% for the CIT group in the primary-prevention cohort (P = 0.032), and 11.5% and 32.0%, respectively, for the MIT and CIT groups in the secondary-intervention cohort (P = 0.044).": [
            " question: What were the cumulative percentages of development and progression in nephropathy after 6 years?",
            " question: What groups were included in the secondary-intervention cohort?"
        ],
        "In neurological tests after 6 years, MIT group showed significant improvement in the nerve conduction velocities, while the CIT group showed significant deterioration in the median nerve conduction velocities and vibration threshold.": [
            " question: In neurological tests after 6 years, what did the MIT group show significant improvement in?"
        ],
        "Although both postural hypotension and the coefficient of variation of R-R interval tended to improve in the MIT group, they deteriorated in the CIT group.": [
            " question: Did postural hypotension and the coefficient of variation of R-R interval improve in the MIT group?"
        ],
        "In conclusion, intensive glycemic control by multiple insulin injection therapy can delay the onset and the progression of diabetic retinopathy, nephropathy and neuropathy in Japanese patients with NIDDM.": [
            " question: How can intensive glycemic control by multiple insulin injection therapy delay the onset and the progression of diabetic retinopathy?"
        ],
        "From this study, the glycemic threshold to prevent the onset and the progression of diabetic microangiopathy is indicated as follows; HbA1c < 6.5%, FBG < 110 mg/dl, and 2-h post-prandial blood glucose concentration < 180 mg/dl.": [
            " question: What questions were asked about the glycemic threshold?"
        ]
    },
    {
        "source_PMID": "7598463",
        "The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive treatment of patients with insulin-dependent diabetes mellitus (IDDM) can substantially reduce the onset and progression of diabetic retinopathy, nephropathy, and neuropathy.": [
            " question: What questions did the DCCT generate?"
        ],
        "The major risk associated with intensive treatment is recurrent hypoglycemia.": [
            " question: What is the risk associated with recurrent hypoglycemia?"
        ],
        "Implementation of intensive treatment recommendations is difficult but should be considered and probably recommended to most patients with IDDM.": [
            " question: Is it difficult to implement intensive treatment recommendations?"
        ],
        "If intensive treatment is impractical, any improvement in glycemic control is probably beneficial.": [
            " question: Is it possible to improve glycemic control without intensive treatment?"
        ],
        "Improved glycemic control should be recommended to most patients with non-insulin-dependent diabetes mellitus (NIDDM).": [
            " question: Is improved glycemic control recommended to most patients with NIDDM?"
        ],
        "The use of insulin in patients with NIDDM is controversial, especially in patients who are overweight, overeating, and minimally symptomatic.": [
            " question: Is insulin used in patients with NIDDM?"
        ]
    }
]